Nirmatrelvir/Ritonavir — Discount Pricing

Other medications in Infectious Disease

• Nitrofurantoin
• Sofosbuvir/Velpatasvir
• Trimethoprim
• Amoxicillin
• Azithromycin
• Bictegravir/Emtricitabine/TAF
• Ciprofloxacin
• Dolutegravir/Lamivudine

What Nirmatrelvir/Ritonavir is approved for (FDA label)

PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Source: Read the full FDA label on DailyMed. Label effective date: February 19, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Nirmatrelvir/Ritonavir (FDA label)

WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7) ]. • Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring [see Drug Interactions (7) ]. • Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed [see Warnings and Precautions (5.1) , Drug Interactions (7) , and Clinical Studies (14) ]. WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a. SPL document ID: d20f905e-5c85-4ad4-ab46-871ce4f6669e. Label effective date: February 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Nirmatrelvir/Ritonavir (FDA label)

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets [see How Supplied/Storage and Handling (16) ] . • Nirmatrelvir is supplied as oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. Each tablet contains 150 mg of nirmatrelvir. • Ritonavir is supplied as white or white to off-white film-coated tablets uniquely identified by the color, shape, and debossing. Each tablet contains 100 mg of ritonavir. • Tablets: nirmatrelvir 150 mg ( 3 ) • Tablets: ritonavir 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a. SPL document ID: d20f905e-5c85-4ad4-ab46-871ce4f6669e. Label effective date: February 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nirmatrelvir/Ritonavir (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥1% and greater incidence than in the placebo group) are dysgeusia and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a. SPL document ID: d20f905e-5c85-4ad4-ab46-871ce4f6669e. Label effective date: February 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nirmatrelvir/Ritonavir (FDA label)

PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product. PAXLOVID is contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. There are certain other drugs for which concomitant use with PAXLOVID should be avoided and/or dose adjustment, interruption, or therapeutic monitoring is recommended.

Source: FDA prescribing information (DailyMed). Set ID: 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a. SPL document ID: d20f905e-5c85-4ad4-ab46-871ce4f6669e. Label effective date: February 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.